Related references
Note: Only part of the references are listed.Global prediction of primary liver cancer incidences and mortality in 2040
Chenxi Li et al.
JOURNAL OF HEPATOLOGY (2023)
Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy
Theodoros Michelakos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer
Giulia Marelli et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma
Stephen T. Muth et al.
CANCER LETTERS (2021)
Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy
Yu-Hung Lee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma
Patrick M. McCarthy et al.
ONCOTARGETS AND THERAPY (2021)
CD40 Agonist Antibodies in Cancer Immunotherapy
Robert H. Vonderheide
ANNUAL REVIEW OF MEDICINE, VOL 71, 2020 (2020)
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
Devalingam Mahalingam et al.
CLINICAL CANCER RESEARCH (2020)
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Christopher Nevala-Plagemann et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory
Wenhao Luo et al.
CANCER CELL INTERNATIONAL (2020)
PCRT16-001: Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic ductal adenocarcinoma (mPDA).
E. Gabriela Chiorean et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Exceptional responses to ipilimumab/nivolumab (ipi/nivo) in patients (pts) with refractory pancreatic ductal adenocarcinoma (PDAC) and germline BRCA or RAD51 mutations.
Gretel Terrero et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
CXCR1/2 blockade to enhance response to immune checkpoint inhibition in an aggressive orthotopic pancreatic adenocarcinoma model.
Nicholas A. Ullman et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer
Yanghee Woo et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2020)
Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future
Eric S Christenson et al.
LANCET ONCOLOGY (2020)
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
Michael Overman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Molecular profiling for precision cancer therapies
Eoghan R. Malone et al.
GENOME MEDICINE (2020)
T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer
Geoffrey Parriott et al.
IMMUNOLOGY (2020)
Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
Ching-Yao Yang et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer
Janina Henze et al.
CANCERS (2020)
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bruno Bockorny et al.
NATURE MEDICINE (2020)
Pancreatic cancer stroma: an update on therapeutic targeting strategies
Abdel N. Hosein et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Zev A. Wainberg et al.
CLINICAL CANCER RESEARCH (2020)
Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
Lin Shui et al.
BMC CANCER (2020)
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Aaron J. Grossberg et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Review of precision cancer medicine: Evolution of the treatment paradigm
Apostolia M. Tsimberidou et al.
CANCER TREATMENT REVIEWS (2020)
Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma
Lin Shui et al.
FRONTIERS IN IMMUNOLOGY (2020)
Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer
Kenji Fujiwara et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud et al.
CANCERS (2020)
Phase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
N. Halama et al.
ANNALS OF ONCOLOGY (2020)
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Adham S. Bear et al.
CANCER CELL (2020)
A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma
Conor O'Neill et al.
SURGERY (2020)
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
Mark H O'Hara et al.
LANCET ONCOLOGY (2020)
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
Roberta Turiello et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
FOLFIRINOX regulated tumor immune microenvironment to extend the survival of patients with resectable pancreatic ductal adenocarcinoma
Meng-Yao Wu et al.
GLAND SURGERY (2020)
Co-inhibition of the TGF-β pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy
Yang Wang et al.
BIOMATERIALS SCIENCE (2020)
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung et al.
CLINICAL CANCER RESEARCH (2019)
Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer
Jun Zhao et al.
NATURE COMMUNICATIONS (2019)
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
Han Yao et al.
NATURE BIOMEDICAL ENGINEERING (2019)
Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy
Qiang Zhang et al.
CANCER RESEARCH (2019)
Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer
Yongwoo David Seo et al.
CLINICAL CANCER RESEARCH (2019)
IOLite: Multipart, phase 1b, dose-finding study of the PD-1 inhibitor dostarlimab in combination with the PARP inhibitor niraparib ± bevacizumab (bev), or with platinum-based chemotherapy ± bev for advanced cancer.
Nashat Y. Gabrail et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
Davide Melisi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment
Chin-King Looi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
O-008Proof of concept of the abscopal effect in MSS GI cancers: A phase 2 study of ipilimumab and nivolumab with radiation in metastatic pancreatic and colorectal adenocarcinoma
A Parikh et al.
ANNALS OF ONCOLOGY (2019)
Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer
Alex B. Blair et al.
CLINICAL CANCER RESEARCH (2019)
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
Li-Chuan Chan et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model
Gulzar Ahmed et al.
MOLECULAR CANCER THERAPEUTICS (2019)
USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity
Xing Huang et al.
CANCER IMMUNOLOGY RESEARCH (2019)
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients
Michal Bassani-Sternberg et al.
FRONTIERS IN IMMUNOLOGY (2019)
Mechanisms Controlling PD-L1 Expression in Cancer
Jong-Ho Cha et al.
MOLECULAR CELL (2019)
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Spencer C. Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention
Jie Chen et al.
CANCERS (2019)
Precision medicine in pancreatic cancer: treating every patient as an exception
Brian Herbst et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Palmitoylation stabilizes PD-L1 to promote breast tumor growth
Yi Yang et al.
CELL RESEARCH (2019)
New therapeutic targets in pancreatic cancer
Eleonora Lai et al.
CANCER TREATMENT REVIEWS (2019)
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Arnaud Scherpereel et al.
LANCET ONCOLOGY (2019)
A Phase II pilot trial of nivolumab (N) plus albumin bound paclitaxel (AP) plus paricalcitol (P) plus cisplatin (C) plus gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC)
Erkut H. Borazanci et al.
CANCER RESEARCH (2019)
A phase I/II study of durvalumab and stereotactic radiotherapy in locally advanced pancreatic cancer
Richard Tuli et al.
CANCER RESEARCH (2019)
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
David Hong et al.
ONCOLOGY (2019)
Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
Thomas A. Mace et al.
GUT (2018)
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2018)
Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1
Christina M. Maher et al.
MOLECULAR CANCER RESEARCH (2018)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
Kaichao Feng et al.
PROTEIN & CELL (2018)
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia-Wei Li et al.
CANCER CELL (2018)
Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer
Andrew J. Rech et al.
CANCER RESEARCH (2018)
IDO1 in cancer: a Gemini of immune checkpoints
Lijie Zhai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2018)
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
Gregory L. Beatty et al.
GASTROENTEROLOGY (2018)
Management of Borderline Resectable Pancreatic Cancer
Diego A. S. Toesca et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
Therapeutic developments in pancreatic cancer: current and future perspectives
John P. Neoptolemos et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
Jung-Mao Hsu et al.
NATURE COMMUNICATIONS (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Combination CD40 agonist and PD-1 antagonist antibody therapy enhances vaccine induced T cell responses in non-immunogenic cancers
Hayley S. Ma et al.
CANCER RESEARCH (2018)
Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
Andrea Wang-Gillam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.
Aitana Calvo et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Jong-Ho Cha et al.
MOLECULAR CELL (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
Derya Kabacaoglu et al.
FRONTIERS IN IMMUNOLOGY (2018)
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours
Amit Maity et al.
BRITISH JOURNAL OF CANCER (2018)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed et al.
CELL (2018)
Oncolytic virus immunotherapy: future prospects for oncology
Junaid Raja et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.
Eileen Mary O'Reilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The Canadian Cancer Trials Group PA. 7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
Daniel John Renouf et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immunotherapy and Prevention of Pancreatic Cancer
Alexander H. Morrison et al.
TRENDS IN CANCER (2018)
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
Jessica S. Brown et al.
BRITISH JOURNAL OF CANCER (2018)
Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer
Jennifer Brooks et al.
CANCER RESEARCH (2018)
INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434)
Yutaka Fujiwara et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy
Jung-Mao Hsu et al.
CANCER RESEARCH (2018)
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
Jun Gong et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
Abul Azad et al.
EMBO MOLECULAR MEDICINE (2017)
The role and therapeutic targeting of IL-6 in rheumatoid arthritis
Masashi Narazaki et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Riccardo Mezzadra et al.
NATURE (2017)
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr et al.
NATURE (2017)
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R. Weichselbaum et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines
Toshifumi Doi et al.
ONCOLOGY REPORTS (2017)
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Claire Vanpouille-Box et al.
NATURE COMMUNICATIONS (2017)
A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma
Paolo D'Arrigo et al.
Oncotarget (2017)
Oncolytic immunotherapy: Conceptual evolution, Current Strategies, and Future Perspectives
Zong Sheng Guo et al.
FRONTIERS IN IMMUNOLOGY (2017)
Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton
Henrick Horita et al.
NEOPLASIA (2017)
Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.
Matthew H. G. Katz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Discovery of IDO1 Inhibitors: From Bench to Bedside
George C. Prendergast et al.
CANCER RESEARCH (2017)
Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
I. H. Sahin et al.
ANNALS OF ONCOLOGY (2017)
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity
Fiona C. Thistlethwaite et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
PD-1/PD-L1 and immunotherapy for pancreatic cancer
Mengyu Feng et al.
CANCER LETTERS (2017)
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
Glen J. Weiss et al.
BRITISH JOURNAL OF CANCER (2017)
A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.
Michael Friedlander et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Andrew J. Gunderson et al.
CANCER DISCOVERY (2016)
Deubiquitination and Stabilization of PD-L1 by CSN5
Seung-Oe Lim et al.
CANCER CELL (2016)
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma
Colin W. Steele et al.
CANCER CELL (2016)
PEGylated recombinant hyaluronidase PH20 (PEGPH20) enhances checkpoint inhibitor efficacy in syngeneic mouse models of cancer
Sanna Rosengren et al.
CANCER RESEARCH (2016)
Emerging Opportunities and Challenges in Cancer Immunotherapy
Theresa L. Whiteside et al.
CLINICAL CANCER RESEARCH (2016)
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
Avery D. Posey et al.
IMMUNITY (2016)
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Hong Jiang et al.
NATURE MEDICINE (2016)
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia-Wei Li et al.
NATURE COMMUNICATIONS (2016)
Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model
Nadia M. Luheshi et al.
ONCOTARGET (2016)
Focal Adhesion Kinase Regulates Fibroblast Migration via Integrin beta-1 and Plays a Central Role in Fibrosis
Xue-Ke Zhao et al.
SCIENTIFIC REPORTS (2016)
A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers
Julie Brahmer et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
Jin Sheng et al.
SCIENTIFIC REPORTS (2016)
Systemic treatment with anti-PD-1 antibody nivolumab in combination with vaccine therapy in advanced pancreatic cancer
Jan Nesselhut et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma
Eric A. Mellon et al.
ACTA ONCOLOGICA (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
Chi-Ping Day et al.
CELL (2015)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer
Freya A. Goumas et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Andrew B. Sharabi et al.
LANCET ONCOLOGY (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Synergistic effect of targeted chemotherapy delivery using theranostic nanoparticles and PD-L1 blockade in an orthotopic mouse pancreatic cancer model
Erica N. Bozeman et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Rafael Winograd et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Dendritic cells generated with PDL-1 checkpoint blockade for treatment of advanced pancreatic cancer
Jan Nesselhut et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Building better monoclonal antibody-based therapeutics
George J. Weiner
NATURE REVIEWS CANCER (2015)
PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
Kevin C. Soares et al.
JOURNAL OF IMMUNOTHERAPY (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
Yu Zhu et al.
CANCER RESEARCH (2014)
Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy
Mara H. Sherman et al.
CELL (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Thorax irradiation triggers a local and systemic accumulation of immunosuppressive CD4+FoxP3+regulatory T cells
Florian Wirsdoerfer et al.
RADIATION ONCOLOGY (2014)
The two faces of IL-6 in the tumor microenvironment
Daniel T. Fisher et al.
SEMINARS IN IMMUNOLOGY (2014)
Clinical application of genetically modified T cells in cancer therapy
Michael H. Kershaw et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2014)
Interleukin-6 Is Required for Pancreatic Cancer Progression by Promoting MAPK Signaling Activation and Oxidative Stress Resistance
Yaqing Zhang et al.
CANCER RESEARCH (2013)
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer-Response
Mario Sznol et al.
CLINICAL CANCER RESEARCH (2013)
Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Bertrand Allard et al.
CLINICAL CANCER RESEARCH (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Gene-engineered T cells for cancer therapy
Michael H. Kershaw et al.
NATURE REVIEWS CANCER (2013)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis
Ryan B. Corcoran et al.
CANCER RESEARCH (2011)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Dendritic cells and immunity against cancer
K. Palucka et al.
JOURNAL OF INTERNAL MEDICINE (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer
Takeo Nomi et al.
CLINICAL CANCER RESEARCH (2007)
Share Paper
